Pediatric Disease Registry in Essential Thrombocythaemia (ET)

Multicentre Paediatric Disease Registry in Essential Thrombocythaemia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01198717

Enrollment

Registered

2010-09-10

Start date

2010-09-28

Completion date

2016-03-01

Last updated

2021-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Thrombocythemia (ET)

Brief summary

The aim of this study is to evaluate the progression of ET in children (aged 6-17years inclusive) over a period of 5 years maximum. The study will also assess how children are diagnosed, treatment options for those children with symptoms and events related to their ET and the outcomes of those treatments.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

6 Years to 17 Years

Healthy volunteers

Inclusion criteria

\- 6 years or over and less than 18 years patient has ET according to the WHO criteria as guidance

Exclusion criteria

* Interventional clinical study participation

Design outcomes

Primary

Measure	Time frame
Treatment effects on platelet count in children ages 6-17 years inclusive.	60 months

Secondary

Measure	Time frame
Drug utilization of cytoreductive therapy in children ages 6-17 years inclusive	60 months

Countries

Czechia, France, Germany, Greece, Italy, Spain, Switzerland, United Kingdom

Outcome results